Insight into human allogenic CAR-T therapy: an open-access dataset

Chimeric antigen receptor T-cell (CAR-T) therapy demonstrates significant efficacy in various cancers, predominantly as a subsequent treatment line following multiple prior therapies. When compared to autologous options, allogeneic CAR-T products offer distinct advantages related to cell quality and cost-effectiveness. Because CAR-T cells differ fundamentally from conventional pharmaceuticals, mathematical modeling is essential to elucidate their exposure–response relationships. However, model utility depends on robust parametrization, which requires high-quality data. Although clinical data are expanding rapidly, challenges remain due to their limited availability and fragmentation across different sources. To address this limitation, this work introduces a comprehensive dataset aggregating human clinical trials that utilize allogeneic CAR-T cells for hematological disorders.